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Histiocytic sarcoma (HS) rarely involves extranodal sites, such as the spleen. We report a unique pediatric case of massive
splenomegaly and refractory Coombs negative hemolytic anemia (CNHA) secondary to HS. The CNHA resolved completely after
an emergent splenectomy.Next generation sequencing (NGS) revealed novel ASXL1, PTPN11, KIT, andTP53mutations, unmasking
a clonal heterogeneity within the same neoplasm.
1. Introduction
Malignant histiocytic disorders such as histiocytic sarcoma
(HS) are rare in the pediatric population [1]. HS commonly
presents with fever, malaise, weight loss, and abdominal pain,
but clinical manifestations are varied. HS can be localized or
fulminant and uncommonly involves extranodal sites such as
skin, bone marrow, soft tissue, and spleen [2]. Fulminant or
disseminated HS is often associated with a poor outcome [2].
HS may occur before or after mature B cell lymphomas,
acute lymphoblastic, and hairy cell leukemia, suggesting that
a common oncogenic cellular origin may exist in some
patients [3, 4]. HS can also be associated with autoim-
mune lymphoproliferative syndrome [5]. The majority of HS
express macrophage or histiocytic markers such as lysozyme,
alpha-antitrypsin, CD68 (KP1 and PGM1), CD163, CD11c,
and CD14 but typically lack Langerhans cell (CD1a and
langerin), follicular dendritic cell (CD21 and CD35), and
myeloid cell (CD33, CD13, and myeloperoxidase) markers.
CD34, CD3, and CD20 (T and B lymphocyte markers,
resp.), melanoma (Melan-A, human melanoma black-45,
and tyrosinase), and carcinoma (cytokeratin) markers are
typically absent [6]. Rarely lineage infidelity may be present
and could lead to misdiagnosis of a lymphoma [7].
We report a case of a 17-year-old who presentedwithmas-
sive splenomegaly and severe Coombs negative hemolytic
anemia (CNHA). The diagnosis of histiocytic sarcoma (HS)
was established after an emergent splenectomy. To our knowl-
edge, HS associated with CNHA in the pediatric population
has not been previously reported.
2. Case Report
A 17-year-old African American male presented to the local
emergency department with fatigue, abdominal pain, jaun-
dice, and worsening pallor, for 2 weeks. On exam, he was pale
and icteric and had tender splenomegaly (spleenwas palpable
5-6 cm below costal margin). Labs revealed a hematocrit
equal to 17%, serum bilirubin equal to 3mg/dL, a negative
Coombs test (direct and indirect), and a platelet count of
39,000. The peripheral smear showed anisopoikilocytosis,
abundant spherocytes, tear drop cells, polychromatophilia,
with normal appearing granulocytes, and decreased platelets
(Figure 2(a)). A bone marrow aspirate revealed a hypercel-
lular marrow, negative for blasts, dysplasia, or hemophago-
cytosis. The local hematologist initiated treatment with oral
prednisone (2mg/kg/day) and weekly rituximab (375mg/m2
for 4 total doses) and administered 2 doses of intravenous
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Figure 1: PET scans. (a) Prechemotherapy PET-CT scan (anterior view) demonstrates marked splenomegaly (white arrows), with multiple
hypermetabolic foci scattered throughout the spleen and in the retroperitoneum (blue arrow).There was a large aggregate of abnormal foci at
the lower edge of the spleen that measured 7 × 6 × 5 cm (black arrow); (b) PET-CT after 6 cycles of CHOP chemotherapy shows no evidence
of disease; (c) recurrent hypermetabolic foci and lymphadenopathy involving multiple sites within the liver (black arrow), peritoneum (blue
arrow), mediastinum (white arrows), and neck (gray arrow).
immunoglobulin (1 gram/kilogram body weight given a week
apart), based on the presumptive diagnosis of a Coombs
negative Evans Syndrome.
However, the hemolytic anemia persisted, and the patient
continued to require 2–4 units of packed RBC transfusions to
keep the hematocrit>25%.The spleen (now below umbilicus)
continued to increase in size and was associated with severe
abdominal pain and distension. He was then referred to
our hematology service for further evaluation. We obtained
additional labs as follows: ALPS panel (negative), cold agglu-
tinins (negative), reticulocyte count (10%), indirect and direct
Coombs testing (negative), bilirubin (5mg/dL, mostly indi-
rect), and serum haptoglobin (undetectable). Flow cytometry
on peripheral blood failed to reveal an abnormal blast
population and demonstrated a normal RBC expression
pattern for CD55 or CD59, excluding acute leukemia or PNH,
respectively, as the probable cause of the presentation. The
urinalysis was negative for hemosiderin or blood. Infectious
work-up for Bartonella, brucellosis, tuberculosis, andmalaria
was negative. We obtained an abdominal PET-CT which
demonstrated marked splenomegaly, with multiple areas of
heterogeneous and hypermetabolic enhancing foci/masses
that were scattered throughout the spleen and also in the
retroperitoneum (Figure 1(a)).These findingswere suggestive
of a lymphoproliferative and neoplastic process.
An urgent open splenectomy was performed. The surgi-
cally removed spleen (Figure 2(b)) was massively enlarged
(weight = 1770 grams, 24 × 14 × 11 cm in size) and very
firm in consistency.There were several hypertrophied vessels
noted in the splenic hilum. Serial sections revealed a red-
brown, congested parenchyma, with numerous gray-yellow
nodules (0.1–2 cm in size), concentrated at the lower edge of
the spleen. A repeat bone marrow aspirate demonstrated a
hypercellular marrow, with trilineage maturation and devoid
of HS or hemophagocytosis.
Histological sections of the spleen revealed sheets of atyp-
ical multinucleated cells with a high nuclear to cytoplasmic
ratio, irregular to round nuclear contour, prominent nucleoli,
and an abundant eosinophilic cytoplasm (Figure 2(c)), with
varying degrees of apoptosis. These neoplastic cells stained
positively for CD45, CD68 PGM and Kp1 (Figures 2(d) and
2(e), resp.), CD14, CD23, fascin, and lysozyme (Figure 2(f))
and were negative for CD34, myeloperoxidase, and S100
protein, confirming the diagnosis of HS [7]. CD20, Pax-
5, CD3, CD30, keratin cocktail, desmin, factor VIII, factor
XIIIa, CD163, CD1a, CD21, CD35, CD123 immunostains, and
BRAFV600E mutation were negative.
We also performed hotspot mutation detection by high-
throughput next generation sequencing (NGS), using opti-
mized oligonucleotide probes [8]. Specimens were reviewed
by a pathologist before processing. Formalin-fixed paraffin-
embedded splenic tissue obtained at the time of diagnosis
was used to isolate DNA. Fifteen full genes (exons only)
as well as additional 39 oncogenic hotspots were analyzed
with highly multiplexed next generation sequencing (Illu-
mina TruSight Myeloid Sequencing Panel) (Supplemen-
tal Table 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/3179147) [8]. Limit of detection
of this assay as established by our laboratory is 1-2% mutant
alleles. The variants were classified according to previously
published guidelines and databases. Low prevalence (<10% of
allele frequency) mutations were detected in the ASLX1, KIT,
PTPN11, and TP53 genes (Supplemental Table 2), along with
multiple variants of unknown significance (not included in
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Figure 2: Peripheral blood smear and histopathology of the spleen. (a) Prechemotherapy peripheral blood smear with anisopoikilocytosis,
numerous spherocytes (white arrows), tear drop cell (black arrow), and decreased platelets; (b) massively enlarged, surgically removed spleen
(weight = 1770 grams; 24 × 14 × 11 cm in size); (c) histological sections of the spleen revealed sheets of atypical cells with a high nuclear to cyto-
plasmic ratio, prominent nucleoli, and an abundant eosinophilic cytoplasm (400xmagnification); (d, e, and f) areas of spleen involvedwithHS
demonstrated strong and diffuse immunoreactivity withmacrophage-specific markers (CD68 PGM (d), CD68 KP1 (e), and lysozyme (f)) [7].
supplemental data), suggesting thatmutated or variant tumor
cells comprised only a minor portion of the malignant clone.
Importantly, the hemolytic anemia and thrombocytope-
nia resolved rapidly and completely after splenectomy. We
then elected to treat our patient with adjuvant CHOP
chemotherapy (cyclophosphamide, doxorubicin, vincristine,
and oral prednisone) [9, 10]. The PET-CT scans after 3
cycles of CHOP and at the end of therapy (Figure 1(b))
demonstrated no residual or recurrent FDG avid lesions.
However, the remission only lasted 3-4 months; recurrent
diseasewas identified in the liver and abdominal lymphnodes
(Figure 1(c)) on a PET scan and confirmed with a supraclav-
icular (neck) lymph node and CT guided liver needle biopsy.
Interestingly, the CNHA did not recur with the relapse.
The relapsed disease was treated with 4 cycles of ICE
(ifosfamide, carboplatin, and etoposide) chemotherapy [11]
followed by an autologous stem cell transplant (using BEAM,
carmustine, etoposide, cytarabine, and melphalan, as a con-
ditioning regimen) for consolidation [12]. Unfortunately, our
patient remained in remission only for 5-6 months, after
transplant, and elected for palliative care.
3. Discussion
Acquired Coombs negative hemolytic anemia (CNHA)
is rare in the adolescent age group. The differential
diagnosis of CNHA (nonimmune hemolysis) associated
with splenomegaly, in pediatric patients, includes both
inherited and acquired causes such as hemoglobinopathies,
RBC enzyme or membrane defects, infections, toxins, HLH,
immunodeficiencies, microangiopathies, and uncommonly
neoplasms [13, 14]. Splenectomy is rarely performed in these
patients but may be indicated in severe refractory immune
mediated hemolysis, recurrent splenic sequestration, or
hypersplenism [15].
Our patient presented with a Coombs negative hemolytic
anemia (CNHA), associated with massive splenic involve-
ment by HS. To our knowledge, this is the first pediatric
report describing this atypical presentation.TheCNHAcould
have resulted from the altered circulation, hypoxia, and acidi-
fication in themassive spleen. An emergent total splenectomy
led to a rapid resolution of CNHA, supporting that notion.
Treatment with rituximab, IVIG, and steroids did not
improve the CNHA.This initial lack of response to rituximab
is, most likely, due to lack of CD20 expression or the existence
of a nonimmune mechanism, such as the extravascular
destruction of RBCs in the spleen, or direct cell mediated
cytotoxicity [16, 17]. There was no lab evidence of significant
microangiopathy (no RBC fragments or schistocytosis) or
hemophagocytic lymphohistiocytosis (HLH) (hemophago-
cytosis, hypertriglyceridemia, low NK activity, or hypofib-
rinogenemia) [18]. In addition, NGS failed to identify high
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prevalence (>10%) oncogenic mutations that could explain
the pathogenesis or the unique presentation of this HS.
Interestingly, the HS infiltrated spleen harbored muta-
tions in the ASLX1, KIT, PTPN11, and TP53 genes (Supple-
mental Table 2). Mutations in ASXL1 have been observed
frequently in acute myelogenous leukemia and myelodys-
plastic syndromes and are associated with a worse outcome
due to an aberrant hematopoiesis [19]. Genomic profiling of
acute myelogenous leukemia has identified somatic variants
in both PTPN11 and KIT genes [20] and TP53mutations [21],
implicating resistant pathways that require further investi-
gation [22]. It is plausible that these cooperating mutations
contributed to HS relapse, in our patient.
4. Conclusion
This case report underscores the importance of ruling out
an occult malignancy as a rare cause of refractory CNHA.
Splenectomy is an effective option to treat CNHA due to
splenic involvement by HS.
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